Work

Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA), ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (TRINITY).

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps9593

Authors: Elizabeth M. Burton, Tara Marie Davidson, Krysta McVay, Denai R. Milton, Rodabe Navroze Amaria, Isabella Claudia Glitza, Jennifer Leigh McQuade, Theresa H. Nguyen, Alexandra Ikeguchi, Adi Diab, Weiyi Peng, Michael A. Davies, Hussein A. Tawbi

Institutions: The University of Texas MD Anderson Cancer Center, University of Houston

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410819712

FWCI: 0.371

Cites:

Cited by: 1

Related to: 10